Introduction {#s1}
============

The large number of common genetic variants associated with prevalent complex diseases suggests that disease pathogenesis involves perturbations to intricate gene networks ([@bib21]). The recently proposed omnigenic model of complex traits highlights the importance of *trans*-regulated networks in understanding causative disease pathways ([@bib11]; [@bib34]). One way of mapping these regulatory networks is to identify the genetic control points of gene co-expression networks in a cell type relevant to the disease of interest. In this way, expression quantitative trait loci (eQTL) studies have revealed regions of the genome that harbour sequence variants affecting the mRNA expression levels of one or more genes ([@bib4]). These approaches identified *trans*-eQTLs, which regulate gene expression that are often observed in clusters, also known as *trans*-eQTL hotspots ([@bib3]; [@bib12]; [@bib41]; [@bib49]). Many of the *trans*-eQTLs discovered to date in different model organisms tend to influence the expression of multiple genes ([@bib3]; [@bib6]; [@bib24]; [@bib28]; [@bib29]; [@bib50]; [@bib59]), which suggests coordinated (network-based) regulatory mechanisms might be perturbed during disease pathogenesis. Although identification of such networks has informed our understanding of gene-gene interactions, their functional validation remains challenging.

Bone-resorbing multinucleated osteoclasts are derived from the monocyte-macrophage lineage ([@bib54]). They display high metabolic activity ([@bib27]) and regulate bone mass, structure and strength. Dysregulation of osteoclastic bone resorption is a major cause of both low and high bone mass disorders including osteoporosis ([@bib36]), and osteopetrosis ([@bib51]), and an important contributor to the pathogenesis of Paget\'s disease ([@bib22]), adolescent idiopathic scoliosis (AIS) ([@bib33]), and inflammatory diseases that affect the skeleton such as rheumatoid arthritis, ankylosing spondylitis and periodontitis ([@bib17]; [@bib37]). Recent genome-wide association studies (GWAS) have identified hundreds of independent polymorphic loci associated with bone diseases in humans, including many that contain osteoclast-related genes ([@bib2]; [@bib18]; [@bib30]; [@bib31]; [@bib38]; [@bib42]; [@bib52]). However, only a few causal genes have been implicated in disease onset and progression, suggesting that activities of complex interacting gene networks play a crucial role in establishing and optimising bone mass and strength, and in the pathogenesis of skeletal disease ([@bib1]).

We previously developed a rapid-throughput skeletal phenotyping pipeline that combines both structural and functional parameters ([@bib8]; [@bib20]). We first applied this multi-parameter phenotyping pipeline to analyse 100 knockout (KO) mice and reported nine new genetic determinants of bone mineralisation, structure and strength ([@bib8]). We then extended our studies to over 500 KO mouse lines and integrated this large-scale phenotype resource with over 1000 conditionally independent SNPs at over 500 loci that significantly associate with bone mineral density (BMD) and fracture in GWAS to provide functional evidence of causation for candidate genes ([@bib30]; [@bib38]; [@bib42]; [@bib53]). These integrated studies demonstrated how large-scale phenotyping and genetic association projects provide systems-level platforms for gene identification in skeletal disorders. Robust systems genetics approaches also incorporate functional assays in a context-dependent cell type such that the effect of genome variation can be investigated to identify cell-specific mechanisms of disease. The osteoclast has an important advantage that, physiologically, its multinucleation capability correlates with its resorptive activity as well as with quantitative in vivo traits such as bone mass, structure and strength ([@bib46]). By contrast, osteoclast-rich osteopetrosis occurs due to impaired osteoclast function despite normal multinucleation and may result from mutations in (i) *TCIRG1*, *CLCN7, OSTM1* or *CA2* deficiency of which impair acidification, or (ii) *SNX10* and *PLEKHM1* deficiency of which impair endosome trafficking ([@bib51]). Thus, we hypothesise that osteoclast gene regulatory networks play a key role to establish and maintain optimal bone structure and strength, and are perturbed in skeletal disease.

We previously investigated the genetic determinants of macrophage multinucleation, using the inbred Wistar Kyoto (WKY) rat strain that displays spontaneous macrophage fusion ([@bib29]; [@bib48]). By mapping eQTLs in fusion-competent primary macrophages, we found a *trans*-regulated gene co-expression network (190 genes) enriched for osteoclast genes that we defined as a 'macrophage multinucleation network' (MMnet) ([@bib29]). MMnet is under the genetic control of the *Trem2* (Triggering Receptor Expressed On Myeloid Cells 2) locus and includes a hub gene, *Bcat1* (Branched chain amino acid transferase 1) that has the greatest number of connections (i.e. co-expression) with other MMnet transcripts. This network contained *trans*-regulated genes previously involved in osteoclastogenesis and we defined a new role for the most significant *trans*-eQTL (*Kcnn4*) in osteoclast multinucleation, bone homeostasis and inflammatory arthritis ([@bib29]).

Here we validate the functional role of MMnet in the regulation of osteoclast multinucleation, resorption and bone mass and strength. We report a correlation between the effects of MMnet gene knockdown on multinucleation and resorption in vitro and the effect on bone mass in vivo. Our study illustrates how the cell- specific function of osteoclast multinucleation and resorption can be used to link genetic variation within a complex network of co-regulated genes to the clinically critical phenotypes of bone mass and strength.

Results {#s2}
=======

MMnet regulates adult bone homeostasis via control of osteoclast multinucleation {#s2-1}
--------------------------------------------------------------------------------

MMnet is a co-expression network comprising 190 osteoclast-enriched eQTLs that are regulated in trans by *Trem2* ([@bib29]). It was generated using primary macrophages from a heterogenous rat population derived from experimental crossing of inbred Wistar Kyoto (WKY) and LEW rats. Macrophages from WKY rats display spontaneous fusion and multinucleation, whereas spontaneous macrophage fusion does not occur in Lewis (LEW) rats ([@bib29]; [@bib48]). Here we show that WKY rats display increased osteoclastogenesis in vitro compared to LEW rats ([Figure 1A--B](#fig1){ref-type="fig"}). We therefore reasoned that WKY and LEW rats should exhibit divergent skeletal phenotypes. Skeletal analysis demonstrated that, compared to LEW rats, WKY rats have decreased bone length, bone mineral content (BMC), trabecular bone volume (BV/TV) and thickness (Tb.Th), together with reduced cortical bone thickness (Ct.Th) and mineral density (BMD) ([Figure 1C--E](#fig1){ref-type="fig"}). These abnormalities resulted in markedly decreased bone strength ([Figure 1D--E](#fig1){ref-type="fig"}). Overall, these data indicate that spontaneous macrophage and osteoclast multinucleation in WKY rats is associated with low bone mass, mineralisation and strength. Thus, these findings suggest that MMnet regulates adult bone homeostasis via its action in osteoclasts to control multinucleation.

![MMnet regulates adult bone homeostasis through osteoclast multinucleation.\
(**A**) Left: Representative images of osteoclasts from Lewis (LEW) and Wistar Kyoto (WKY) rats stained with Giemsa stain. Right: number of osteoclasts with \>10 nuclei from LEW and WKY rats. (**B**) Relative mRNA expression of *Nfatc1* and *Trem2* determined by qRT-PCR following osteoclast culture (n = 3/group). (**C**) (Left) Pseudocoloured X-ray microradiography images of femurs from male Lewis (LEW) and Wistar-Kyoto (WKY) rats (low BMC blue and green and high BMC red and pink) showing decreased femur length in WKY animals (scale bar = 2 mm). (Right) Cumulative frequency histogram showing reduced BMC in WKY rats; (n = 4 \*\*p\<0.01 vs. WT; Kolmogorov--Smirnov test). (**D**) Representative load displacement curves from femur three-point bend testing. (**E**) Micro-CT analysis of distal femur trabecular bone (trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular bone mineral density (Tb.BMD) and structure model index (SMI)) (Upper panel), micro-CT analysis from mid-diaphysis cortical bone (cortical thickness (Ct.Th), bone area (Ct.Ar), internal diameter (Int.Dia) and cortical bone mineral density (Ct.BMD)) (middle panel) and femur three-point-bend testing (lower panel) (Mean ± SD; n = 4 \*p\<0.05, \*\*p\<0.01 LEW vs WKY Student's t-test). (**F**) MMnet comprising 190 *trans*-eQTLs under the master regulatory locus (Trem2, highlighted in red). Each gene in the network is represented as a circle (node), and the genes that are GWAS hits (See also [Table 1](#table1){ref-type="table"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}) are highlighted in blue. Connecting lines indicate co-expression between the two transcripts.\
Figure 1---source data 1.MMnet GWAS hits and their association with heel bone mineral density.](elife-55549-fig1){#fig1}

MMnet genes are enriched in human skeletal GWAS variants {#s2-2}
--------------------------------------------------------

We first determined whether MMnet eQTL genes are significantly enriched for GWAS loci associated with bone disorders in humans. In comparison with the background set of eQTLs (1448 eQTLs that were previously mapped in multinucleating macrophages \[[@bib29]\], MMnet was generally enriched for bone-related GWAS loci (p=0.0085, hypergeometric test, [Table 1](#table1){ref-type="table"}) and more specifically for heel bone mineral density associated GWAS variants ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}), which had the most significant enrichment (20 loci, p=4.49×10^−3^, hypergeometric test, [Table 1](#table1){ref-type="table"}). Consistent with the decreased bone length observed in WKY rats, MMnet was also significantly enriched for body height variants (24 loci, p=1.86×10^−2^, hypergeometric test, [Table 1](#table1){ref-type="table"}). In addition to enrichment for GWAS loci associated with skeletal traits, 9 MMnet genes have also been implicated in the pathogenesis of rare monogenic skeletal disorders (*CTSK*, *FAM20C*, *FLNA*, *FN1*, *IDUA*, *IL1RN*, *MANBA*, *MET*, *MMP9*) ([@bib43]). These results demonstrate that MMnet is conserved in humans and implicated in the regulation of skeletal development and bone homeostasis ([Figure 1F](#fig1){ref-type="fig"}).

###### MMnet is significantly enriched for variants that associate with different bone traits.

Single nucleotide polymorphisms (SNPs) significantly associated with the reported GWAS traits were interrogated in two datasets: the background dataset which includes all the eQTLs (posterior probability \>80% see Materials and methods) and MMnet gene set. The enrichment was then tested over the background using a hypergeometric test. The significantly enriched traits are shown in bold.

  GWAS trait                                 Number of eQTLs genes (background) with at least one GWAS hit   Number of MMnet genes with at least one GWAS hit   Frequency (%) eQTLs genes (background) with at least one GWAS hit   Frequency (%) MMnet genes with at least one GWAS hit   P-value MMnet enrichment over background (hypergeometric test)
  ------------------------------------------ --------------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------
  **All GWAS combined**                      **299**                                                         **41**                                             **20.3%**                                                           **27.7%**                                              **0.0085**
  **Heel bone mineral density**              **117**                                                         **20**                                             **8.0%**                                                            **13.5%**                                              **0.0045**
  **Osteoarthritis**                         **9**                                                           **3**                                              **0.6%**                                                            **2.0%**                                               **0.0083**
  **Psoriatic arthritis**                    **2**                                                           **1**                                              **0.1%**                                                            **0.7%**                                               **0.0101**
  **Body height**                            **165**                                                         **24**                                             **11.2%**                                                           **16.2%**                                              **0.0186**
  Bone quantitative ultrasound measurement   4                                                               1                                                  0.3%                                                                0.7%                                                   0.0527
  Bone density                               16                                                              3                                                  1.1%                                                                2.0%                                                   0.0686
  Hip bone mineral density                   5                                                               1                                                  0.3%                                                                0.7%                                                   0.0821
  Spine bone mineral density                 7                                                               1                                                  0.5%                                                                0.7%                                                   0.1509
  Bone fracture                              3                                                               0                                                  0.2%                                                                0.0%                                                   0.2727
  Ankylosing spondylitis                     4                                                               0                                                  0.3%                                                                0.0%                                                   0.3460
  Periodontitis                              4                                                               0                                                  0.3%                                                                0.0%                                                   0.3460
  Rheumatoid arthritis                       15                                                              1                                                  1.0%                                                                0.7%                                                   0.4550
  Adolescent idiopathic scoliosis            60                                                              5                                                  4.1%                                                                3.4%                                                   0.5723
  Bone mineral content measurement           1                                                               1                                                  0.1%                                                                0.7%                                                   \-
  Lumbar disc degeneration                   1                                                               1                                                  0.1%                                                                0.7%                                                   \-
  Osteitis deformans                         1                                                               0                                                  0.1%                                                                0.0%                                                   \-

BCAT1 maintains normal bone mass and strength by regulating osteoclast multinucleation and function {#s2-3}
---------------------------------------------------------------------------------------------------

To validate the role of MMnet, we investigated the effect of the MMnet hub gene *Bcat1* on osteoclast multinucleation and resorption, and bone mass ([Figure 2A](#fig2){ref-type="fig"}). 12 week-old male *Bcat1*^-/-^ mice had high bone mass characterised by increased cortical thickness (Ct.Th), trabecular bone volume (BV/TV), number (Tb.N) and thickness (Tb.Th), and reduced trabecular separation (Tb.Sp) and structural model index (SMI) (n = 8 per genotype) ([Figure 2B--C](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Biomechanical 3-point bend testing demonstrated that *Bcat1*^-/-^ mice had enhanced bone strength characterised by increased yield, maximum and fracture loads and stiffness ([Figure 2C](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Furthermore, static histomorphometry showed that *Bcat1*^-/-^ mice had decreased osteoclast surface (Oc.S/BS) and number (Oc.N/BS), suggesting their high bone mass phenotype results from impaired osteoclast activity ([Figure 2D](#fig2){ref-type="fig"}). Moreover, *Bcat1^-/-^* mice had increased amounts of retained cartilage within both trabecular and cortical bone, suggesting impaired osteoclastic resorption during bone modelling and remodelling ([Figure 2---figure supplement 1D--E](#fig2s1){ref-type="fig"}). Consistent with this, siRNA-mediated knockdown of *BCAT1* expression in human osteoclasts in vitro inhibited multinucleation and resorption by 60% ([Figure 2E--F](#fig2){ref-type="fig"}). By comparison, knockdown of *DCSTAMP*, a master regulator of osteoclast and macrophage membrane fusion ([@bib57]; [@bib58]), resulted in 90% inhibition of osteoclast multinucleation and resorption ([Figure 2E--F](#fig2){ref-type="fig"}). Taken together, these data demonstrate an important new role for BCAT1 in osteoclast formation and function, and the physiological maintenance of adult bone mass and strength.

![*Bcat1* deficiency results in high bone mass due to decreased osteoclast fusion.\
(**A**) Location of *Bcat1* as the MMnet hub (left panel). Skeletal phenotyping of *Bcat1*^-/-^ mice using X-ray microradiography, micro computed tomography (micro-CT) and three point bending testing (right panel). (**B**) Micro-CT images of distal femur trabecular bone and mid-diaphysis cortical bone in wild-type (WT) and *Bcat1*^-/-^ mice (upper panel) (scale bar = 200 μm). Trabecular bone volume/tissue volume (BV/TV) and cortical thickness (Ct.Th) are shown in the lower panel; (Mean ± SD; n = 8 per genotype, \*\*p\<0.01, \*\*\*p\<0.001 vs WT Student's t-test). (**C**) Representative load displacement curves from femur three-point bend testing (upper panel). Fracture load and stiffness are shown in the lower panel; (Mean ± SD; n = 8 mice per genotype, \*\*p\<0.01 vs WT Student's t-test). (**D**) Representative tartrate-resistant acid phosphatase (TRAP) stained sections from the distal femur of WT and *Bcat1*^-/-^ mice showing osteoclasts in red (left panel). Quantification of the osteoclast surface/bone surface (Oc.S/BS) and osteoclast number/bone surface (N.Oc/BS) (right panel) (scale bar = 100 µm); (Mean ± SD; n = 8 per genotype, \*p\<0.05, \*\*\*p\<0.001 vs WT Student's t-test). (**E**) Representative images of TRAP+ multinucleated osteoclasts (upper panel) (scale bar = 40 µm) and hydroxyapatite resorption (lower panel) (scale bar = 1 mm) 2 days after siRNA transfection. (**F**) Percentage inhibition of multinucleation compared to scrambled siRNA (left panel) and percentage inhibition of hydroxyapatite resorption compared to scrambled siRNA (right panel); (Mean ± SD from n = 4 donors, \*\*p\<0.01, \*\*\*p\<0.001 vs scrambled siRNA, one-sample-t test).](elife-55549-fig2){#fig2}

MMnet genes have counter regulatory roles in the maintenance of adult bone mass and strength {#s2-4}
--------------------------------------------------------------------------------------------

To investigate whether individual MMnet genes regulate skeletal homeostasis, we studied all the MMnet genes for which the Wellcome Trust Sanger Institute, as part of the IMPC, had generated KO mice. Rapid-throughput phenotyping ([@bib8]; [@bib18]; [@bib30]; [@bib31]; [@bib38]; [@bib42]) of samples from 16 week-old female mice with deletion of 12 MMnet genes (*Appl2^-/-^*, *Atp8b2^+/-^*, *Deptor^-/-^*, *Dot1l^+/-^*, *Egfr^+/-^*, *Eml1^-/-^*, *Eps15^-/-^*, *Igsf8^-/-^*, *Pik3cb^-/-^*, *Rnf125^-/-^*, *Slc1a4^-/-^*, *Tgfb1i1^-/-^* mice) was performed using X-ray microradiography, micro-CT and biomechanical testing ([Figure 3A](#fig3){ref-type="fig"}). Six of the 12 MMnet KO mouse lines exhibited abnormal skeletal phenotypes, whereas *Dot1l^+/-^*, *Egfr^+/-^*, *Eps15^-/-^*, *Rnf125^-/-^*, *Slc1a4^-/-^* and *Tgfb1i1^-/-^* mice displayed no skeletal abnormalities ([Figure 3B](#fig3){ref-type="fig"}). *Igsf8^-/-^* mice had decreased femur length ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}; *Pik3cb*^-/-^ (increased BV/TV and Tb.N), *Appl2^-/-^* (increased BV/TV) and *Atp8b2^+/-^* (increased BV/TV) mice had high bone mass; whereas *Deptor^-/-^* (decreased BV/TV and Tb.N) mice had low bone mass ([Figure 3C--D](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Biomechanical testing demonstrated decreased bone strength in *Atp8b2^+/-^* (decreased femur stiffness), *Deptor^-/-^* (decreased vertebral stiffness) and *Eml1^-/-^* (decreased vertebral stiffness) mice ([Figure 3E--F](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}).

![MMnet regulates bone mass.\
(**A**) The location of the 12 MMnet genes for which knockout mice were available are highlighted in the network. (**B**) Venn diagram showing mutant strains with outlier phenotypes for bone mass, bone strength and bone length. (**C**) Representative micro-CT images of distal femur trabecular bone and mid diaphyseal cortical bone from WT and mutant mice (scale bar = 200 μm). (**D**) Graphs show trabecular bone volume (BV/TV), trabecular number (Tb.N) and trabecular separation (Tb.Sp). Grey box represents WT reference mean + / - 2 SD (n = 320, 16 week old, female C57BL/6 WT mice). (**E**) Representative load displacement curves for femur three-point bend testing and vertebral compression. (**F**) Femur stiffness (Fem.stiffness) and vertebral stiffness (vert.stiffness). Data from individual mice are shown as black dots and mean value by a red line (n = 2 or six per genotype). Parameters outside the WT reference range are indicated by an asterisk \*.\
Figure 3---source data 1.Results of high-throughput MMnet mouse knockout skeletal phenotyping.](elife-55549-fig3){#fig3}

Human MMnet orthologues regulate osteoclast multinucleation and resorption {#s2-5}
--------------------------------------------------------------------------

To investigate whether the divergent skeletal phenotypes identified in MMnet knockout mice correlate with osteoclast multinucleation and resorption in vitro, we determined the functional consequences of siRNA-mediated knockdown of 11 human orthologues of these MMnet genes in human osteoclasts (*TGFB1I1* was not expressed). The MMnet gene *DCSTAMP* was included as a positive control ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). For all 11 MMnet genes, siRNA-mediated knockdown resulted in a greater than 80% reduction in mRNA expression and did not affect cell viability ([Figure 4---figure supplement 1B--C](#fig4s1){ref-type="fig"}). The number of nuclei in each TRAP+ osteoclast was determined following siRNA knockdown ([Figure 4B--D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1D--E](#fig4s1){ref-type="fig"}). The functional consequences of in vitro siRNA knockdown correlated with the skeletal consequences of gene deletion in vivo. Knockdown of *DOTL1*, *EPS15* and *RNF125* had no effect on osteoclast multinucleation or resorption ([Figure 4B--D](#fig4){ref-type="fig"}) and the skeletal phenotype of the corresponding knockout mice was also unaffected ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Furthermore, knockdown of *APPL2* inhibited osteoclast resorption and knockdown of *PIK3CB* and *ATP8B2* inhibited both multinucleation and resorption ([Figure 4B--D](#fig4){ref-type="fig"}) whilst the corresponding knockout mice displayed increased bone mass ([Figure 3C--D](#fig3){ref-type="fig"}). By contrast, knockdown of *DEPTOR* resulted in a marked stimulation of both multinucleation and resorption ([Figure 4B--D](#fig4){ref-type="fig"}), and *DEPTOR* deficient mice had reduced bone mass and vertebral stiffness ([Figure 3C--F](#fig3){ref-type="fig"}). Overall, the effects of mRNA knockdown of MMnet genes on in vivo osteoclast multinucleation and resorption were concordant and strongly correlated (*R*^2^ = 0.76; p\<0.001) ([Figure 4E](#fig4){ref-type="fig"}). Moreover, the effect of knockdown of MMnet genes on osteoclast resorption was also strongly and inversely correlated with trabecular bone mass (BV/TV) in knockout mice (*R*^2^ = 0.65; p\<0.01) ([Figure 4F](#fig4){ref-type="fig"}).

![MMnet regulates human osteoclast multinucleation and resorption in vitro.\
(**A**) The location of the 11 MMnet genes for which knockout mice were available, and for which there are human orthologues. The master regulator of macrophage fusion *Dcstamp* is highlighted in red. (**B**) Representative images of TRAP+ osteoclasts (Top panel) (scale bar = 40 µm) and hydroxyapatite resorption (Bottom panel) (scale bar = 1 mm) following siRNA knockdown for *DCSTAMP*, *PIK3CB*, *ATP8B2*, *APPL2* and *DEPTOR.* (**C**) Graphs show the frequency of multinucleated cells (\>4 nuclei) following siRNA knockdown as a percentage of the scramble siRNA control; n = 4 donors. (**D**) Hydroxyapatite resorption following siRNA knockdown as a percentage of the scramble siRNA control; n = 4 donors. (For (**C**) and (**D**): Mean ± SD from n = 4 donors, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs scrambled siRNA, one-sample-t test). (**E**) Pearson correlation between human osteoclast multinucleation and resorptive activity following siRNA knockdown of 12 MMnet genes compared to control (R^2^ = 0.76; p\<0.001) (**F**) Pearson correlation between human osteoclast resorption activity following si-RNA knockdown of 11 MMnet genes compared to control and BV/TV in the corresponding 11 MMnet knockout mouse strains (R^2^ = 0.65; p\<0.01).](elife-55549-fig4){#fig4}

These findings demonstrate that the effects of MMnet gene deletion on the skeletal phenotype of knockout mice result, at least in part, from the direct consequences of gene deletion on osteoclast multinucleation and function, and that MMnet contains genes with important counter regulatory roles in the physiological control of adult bone mass and strength.

MMnet regulates bone mass and strength via direct actions in the macrophage-osteoclast lineage {#s2-6}
----------------------------------------------------------------------------------------------

MMnet contains 190 genes, of which 178 are annotated, and among these genes there are known regulators of osteoclast multinucleation (*Dcstamp*, *Mmp9*, *Ctsk*) but the majority of MMnet genes require further investigation. To determine if MMnet genes regulate adult bone mass and strength by direct actions in osteoclasts we developed a prioritisation pipeline to identify a novel and tractable MMnet gene to target for cell-specific gene deletion in the macrophage-osteoclast cell lineage. To identify potential novel and tractable candidates we applied a bespoke in silico filtering to the 178 annotated MMnet genes. The following criteria were used as a stepwise prioritisation filter ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}): (i) conserved expression in human osteoclasts; (ii) conserved expression in mouse macrophages; (iii) unknown function in osteoclastogenesis (Pubmed, accessed December 2017); (iv) availability of the mouse model (<http://www.informatics.jax.org/>); (v) strength of the MMnet eQTL (R^2^ \>1) ([@bib29]; (vi) Membrane receptors with pharmacologically tractable signalling pathways ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). This prioritisation process identified five candidate MMnet genes (*FGR*, *LAT2*, *MYOF*, *FCGRT*, and *SLC40A1*) ([Figure 5---figure supplement 1A--B](#fig5s1){ref-type="fig"}). To identify the most robust regulator of osteoclast multinucleation we determined the consequences of siRNA-mediated knockdown of these five genes in human osteoclasts. Knockdown of all five MMnet genes resulted in greater than 40% inhibition of multinucleation ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Most strikingly, knockdown of *SLC40A1* (encoding the mammalian iron transporter, ferroportin) resulted in more than 80% inhibition of multinucleation, an effect comparable with that of the master regulator *DCSTAMP* ([Figure 5---figure supplement 1C--D](#fig5s1){ref-type="fig"}).

Consequently, SLC40A1 was prioritised for further investigation and we generated a myeloid lineage-specific knockout of *Slc40a1* by crossing *Slc40a1*^flox/flox^ mice with LysM-cre mice. Femurs from 16 week-old male and female mutant Slc40a1 conditionnal KO (cKO) and Control mice were analysed by X-ray-microradiography, microCT and 3-point bend testing (n = 8 per sex per genotype). Slc40a1 cKO mice had greatly increased bone mass characterised by increased BMC ([Figure 5B--C](#fig5){ref-type="fig"}), cortical thickness (Ct.Th), trabecular BV/TV, Tb.N and Tb.Th compared to littermate controls ([Figure 5C--D](#fig5){ref-type="fig"}, [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). This high bone mass phenotype was associated with markedly increased bone strength characterised by increased yield, maximum and fracture loads ([Figure 5C--D](#fig5){ref-type="fig"}, [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). Consistent with this, histomorphometic analysis demonstrated decreased osteoclast surfaces (Oc.S/BS) in Slc40a1 cKO mice ([Figure 5E](#fig5){ref-type="fig"}) and Slc40a1 cKO mice had increased amounts of retained cartilage within trabecular bone, consistent with impaired osteoclastic bone resorption and abnormal bone remodelling ([Figure 5---figure supplement 2 B, C](#fig5s2){ref-type="fig"}). siRNA-mediated knockdown of *SLC40A1* expression, in human osteoclasts in vitro, inhibited osteoclast resorption by more than 85% ([Figure 5F--G](#fig5){ref-type="fig"}). Taken together, these data demonstrate that the MMnet gene, *Slc40a1,* acts as an important determinant of adult bone mass and strength by directly regulating osteoclast multinucleation and function.

![Myeloid-specific deletion of *Ferroportin* results in increased bone mass and strength due to impaired osteoclast multinucleation and function.\
(**A**) Location of *Slc40a1* in MMnet. (**B**) Cumulative frequency histogram of relative BMC; n = 8 per genotype. \*\*\*p\<0.001 vs. WT by Kolmogorov--Smirnov test. (**C**) Representative X-ray microradiography images of femurs from male Control and Slc40a1 cKO mice. Pseudocoloured images indicating low BMC (blue and green) and high BMC (red and pink) are shown in the left panel (scale bar = 1 mm). Micro-CT images of distal femur trabecular bone and mid-diaphysis cortical bone (middle panel) (scale bar = 200 μm). Representative load displacement curves from femur three-point bend testing (right panel). (**D**) Trabecular bone volume (BV/TV) and cortical thickness (Ct.Th), femur maximum load and fracture load. (**E**) Representative TRAP-stained femur sections from Control and Slc40a1 cKO mice showing osteoclasts stained in red (left panel). Osteoclast surface (Oc.S/BS) and osteoclast number (N.Oc/BS) (right panel) (scale bar = 100 µm); (For (**D**) and (**E**): Mean ± SD; n = 8 per genotype, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs Control Student's t-test). (**F**) Representative images of hydroxyapatite resorption (scale bar = 1 mm) following *DCSTAMP* and *SLC40A1* si-RNA knockdown. (**G**) Inhibition of osteoclast hydroxyapatite resorption following *DCSTAMP* and *SLC40A1* siRNA knockdown; (Mean ± SD from n = 4 donors, \*\*\*p\<0.001 vs scrambled siRNA, one-sample-t test).\
Figure 5---source data 1.Prioritisation pipeline to identify a novel and tractable MMnet gene.](elife-55549-fig5){#fig5}

Discussion {#s3}
==========

In this study, we took advantage of an unique *trans*-eQTL network (MMnet) in multinucleating rat primary macrophages that is enriched for osteoclast genes. The parental rat strains used to generate MMnet (WKY and LEW) had opposing skeletal phenotypes and rate of osteoclast multinucleation. Spontaneous fusion of WKY macrophages in vitro was associated with decreased bone length, mass, and strength in vivo, suggesting that genetic determinants of osteoclast multinucleation directly affect bone development and maintenance. These results implicate MMnet in the physiological regulation of adult bone mass and strength.

Next, we determined whether MMnet is enriched for GWAS variants associated with skeletal traits and showed enrichment for heel bone mineral density, body height, osteoarthritis and psoriatic arthritis. These results confirm conservation of MMnet in humans and demonstrate associations between MMnet and osteoclast multinucleation and bone mass. Furthermore, the association of MMnet with osteoarthritis suggests involvement of osteoclasts in articular cartilage degradation, an area that is gaining increasing attention ([@bib23]; [@bib35]).

To validate the function of MMnet in vivo, we first investigated the role of the hub gene, *Bcat1*, in knockout mice and demonstrated important new roles for BCAT1 in osteoclast formation and function, and the physiological maintenance of adult bone mass and strength. These results demonstrate that MMnet has a critical homeostatic role in bone that is conserved in rodents and humans. Furthermore, they specifically implicate branched chain amino acid (BCAA) metabolism in osteoclast-mediated bone homeostasis and are consistent with our recent observation that osteoclast numbers and severity of collagen-induced arthritis are also reduced following pharmacological inhibition of BCAT1 in mice ([@bib45]). BCAT1 activity controls intracellular leucine, a known activator of mammalian target of rapamycin complex 1 (mTORC1) signalling ([@bib5]), suggesting that MMnet may directly regulate mTORC1-dependent bone homeostasis and inflammation via the hub gene *Bcat1*.

To investigate further the homeostatic roles of MMnet in the maintenance of adult bone mass and strength, we analysed knockout mice with deletion of 12 unselected MMnet genes and demonstrated significant outlier phenotypes in six of these lines, which include both known *Pik3cb* ([@bib25]; [@bib26]; [@bib32]) and unknown (*Atp8b2*, *Igsf8*, *Eml1*, *Appl2, and Deptor*) regulators of skeletal homeostasis. Deletion of *Pik3cb, Appl2* and *Atp8b2* resulted in increased bone mass whereas deletion of *Deptor* resulted in decreased bone mass and strength, suggesting MMnet represents a conserved and complex homeostatic counter-regulatory network that serves to optimise bone structure and strength. Consistent with this, deletion of MMnet's strongest *trans*-eQTL *Kcnn4* results in increased bone mass ([@bib29]) as did deletion of *Dcstamp,* the master regulator of membrane fusion ([@bib57]). Nevertheless, although (i) *BCAT1*, *PIK3CB, ATP8B2*, and *APPL2* knockdown in vitro resulted in impaired osteoclast multinucleation and resorption in humans, and (ii) *Bcat1, Pik3cb, Atp8b2*, and *Appl2* deletion in vivo resulted in increased trabecular bone mass, only *Bcat1* deficient mice exhibited increased cortical thickness and bone strength. These findings may refect that (i) *Bcat1* deletion has the greatest effect on osteoclast multinucleation and function in vivo, (ii) *Atp8b2* mice were heterozygotes, (iii) trabecular bone is more sensitive than cortical bone to abnormalities of osteoclastic resorption, and (iv) cortical bone parameters are the major determinants of bone strength. However, since these genetically modified mice have global gene deletions, the variation in skeletal phenotypes may also result from the consequences of gene deletion in non-monocyte/macrophage lineages.

Overall, these studies reveal a common molecular pathway within MMnet that regulates osteoclast multinucleation and function as well as bone mass. Thus, at least four MMnet genes (*Trem2*, *Bcat1*, *Pik3cb* and *Deptor*), that include the network master regulator (*Trem2)* and network hub (*Bcat1)*, act within the Trem2-Pi3K-mTORC1 pathway ([@bib5]; [@bib44]; [@bib47]; [@bib55]). mTORC1 protein kinase comprises a complex of proteins that includes DEPTOR ([@bib47]), a regulator of cell growth and metabolism that is essential for osteoclast formation ([@bib27]). While *Trem2* ([@bib55]), *Bcat1* ([@bib5]) and *Pik3cb* ([@bib44]) are positive regulators of mTORC1, *Deptor* inhibits mTORC1 activity ([@bib47]). Significantly, the divergent effects of these genes on activity of the mTORC1 signalling pathway correlate precisely with the effects of gene knockdown or deletion on osteoclast multinucleation and function in vitro and on skeletal phenotype in vivo. Thus, knockdown or deletion of *Bcat1* and *Pik3cb* results in decreased osteoclast multinucleation and resorption, and increased bone mass, whereas knockdown or deletion of *Deptor* results in opposite cellular and in vivo phenotypes. Together, these data suggest a pivotal and integrated counter-regulatory role for the Trem2-Pi3K-mTORC1 pathway in osteoclast multinucleation and function, and the homeostatic control of bone mass, and may thus provide novel therapeutic targets for the inhibition of bone loss.

Overall, these studies demonstrate that MMnet regulates bone mass and strength via important effects on osteoclast multinucleation and function. Nevertheless, it is important to recognise that primary actions of MMnet genes in osteoclasts may secondarily regulate osteoblastic bone formation. Alternatively, MMnet genes may have direct cell autonomous effects in the osteoblast lineage. Thus, direct and indirect effects of MMnet genes in osteoblast may influence the skeletal phenotypes observed in mutant mice. The role of osteoblasts has not been investigated here, and this represents an important limitation of the study.

Finally, we investigated the role of the iron transporter ferroportin, encoded by the MMnet gene *Slc40a1*, in the osteoclast lineage. Ferroportin was identified as a powerful inhibitor of human osteoclast multinucleation and function in vitro, with a potency equivalent to *Dcstamp* ([Figure 5](#fig5){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Generation of mice with conditional deletion of *Slc40a1* in the macrophage-osteoclast lineage using *LysMCre* mice was consistent with in vitro multinucleation and resulted in a phenotype of increased bone mass and strength ([Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Thus, *Slc40a1* regulates bone structure and strength via direct actions in the macrophage-osteoclast lineage, further supporting the conclusion that MMnet plays a key role in the physiological regulation of bone mass by osteoclasts.

Nevertheless, Wang and colleagues ([@bib56]) recently reported that deletion of *Slc40a1* in the myeloid lineage using *LysMCre* mice causes decreased bone mass and mineralisation in female, but not male, mice. Wang et al also reported that deletion of *Slc40a1* in terminally differentiated osteoclasts using *CtskCre* mice resulted in no skeletal abnormalities in either sex. The discordance between our findings and those reported by Wang et al may be due to differences in the age at which mice were phenotyped and the strain of *Slc40a1* floxed mice investigated (*C57BL/6N-Slc40a1^tm1c(EUCOMM)Hmgu/H^* in this study compared to *129S-Slc40a1^tm2Nca/J^* by Wang and colleagues). Although it is clear that ferroportin acts directly in the macrophage-osteoclast lineage, further longitudinal studies will be required to define its temporal effects on bone mass and strength, whilst studies with the different floxed strains may be required to determine whether modifier genes influence the skeletal response to deletion of *Slc40a1*.

Systems genetics studies use naturally occurring genetic variation to identify gene networks that are associated with the trait of interest in disease-relevant cells ([@bib7]). Systems genetics approaches in osteoblasts and osteoclasts have been previously carried out to identify genes that are implicated in skeletal homeostasis ([@bib13]; [@bib14]; [@bib19]; [@bib40]; [@bib39]). Here, we have used systems genetics approaches to demonstrate that a complex *trans*-eQTL network (MMnet) facilitates homeostatic control of bone mass via its effects on osteoclast fusion and function that are mediated in large part by the mTOR pathway. This physiologically important network is conserved in rats, mice and humans and its identification will lead the way to an understanding of the gene-gene interactions and network-based therapeutic approaches that may be used in osteoclast-mediated inflammatory disease or to prevent bone loss.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

14 week-old male Wistar-Kyoto (WKY/NCrl) and Lewis (LEW/Crl) rats were purchased from Charles River. *Bcat1* knockout (*Bcat1*^-/-^) and wild-type (WT) littermate mice were previously described ([@bib5]) and maintained according to protocols approved by the University of Virginia Animal Care and Use Committee. To rederive *Slc40a^flox/flox^* mice, sperm from conditional-ready heterozygous *Slc40a1*-floxed mice (C57BL/6N-Slc40a1^tm1c(EUCOMM)Hmgu/H^) was obtained from MRC Harwell and used for in vitro fertilisation of C57BL/6N female mice. LysM-Cre mice (*Lyz2*^tm1(cre)Ifo^) were obtained from The Jackson Laboratory. *Slc40a1^flox/flox^* and LysM-Cre mice were crossed to generate Slc40a1 mice in which *Slc40a1* is deleted in cells of the monocyte-macrophage-osteoclast lineage (cKO). *Slc40a1^flox/flox^* (called Control) littermates were used as controls in all experiments. All animals were housed in standard caging on a 12-hr-light cycle and provided with free access to chow and water.

Tissues were collected and placed in either 70% ethanol or 10% neutral buffered formalin for 24 hr prior to storage in 70% ethanol. Samples were randomly assigned to batches for rapid-throughput analysis. All studies were performed in accordance to the U.K. Animal (Scientific Procedures) Act 1986, the ARRIVE guidelines, the EU Directive 2010/63/EU for animal experiments and practices prescribed by the National Institutes of Health in the United States.

The International Mouse Phenotyping Consortium (IMPC: <http://www.mousephenotype.org>) and the International Knockout Mouse Consortium (IKMC) are generating null alleles for all protein-coding genes in mice on a C57BL/6 genetic background ([@bib15]). The Origins of Bone and Cartilage Disease Programme (OBCD) is undertaking a validated rapid-throughput multiparameter skeletal phenotype screen ([@bib8]; [@bib20]) of mutant mouse lines generated by the Wellcome Trust Sanger Institute as part of the IKMC and IMPC effort.

Digital X-ray microradiography {#s4-2}
------------------------------

Femurs and caudal vertebrae 6 and 7 from 16 week-old mice and 14 week-old rats were fixed in 70% ethanol. Soft tissue was removed and digital X-ray images were recorded at 10 µm pixel resolution using a Faxitron MX20 variable kV point projection X-ray source and digital image system (Qados, Cross Technologies plc, UK) operating at 26 kV and 5x magnification. Bone mineral content (BMC) was determined relative to steel, aluminium and polyester standards as described ([@bib9]). Images were calibrated with a digital micrometer and long bone and vertebra lengths were determined ([@bib8]; [@bib9]).

Micro-computerised tomography (micro-CT) {#s4-3}
----------------------------------------

Mouse and rat femurs were analysed by micro-CT (Scanco uCT50, 70 kV, 200 μA, 0.5 mm aluminium filter) as described ([@bib8]). Measurements included cortical bone parameters (cortical thickness (Ct.Th), cortical bone mineral density (Ct.BMD), internal diameter (Int.Dia) and bone area (Ct.Ar) at 10 μm^3^ voxel resolution in a 1.5 mm^2^ region centred on the mid-shaft region 56% of the way along the length of the femur distal to the femoral head, and trabecular parameters (bone volume (BV/TV), trabecular number (Tb.N), thickness (Tb.Th), spacing (Tb.Sp), structure model index (SMI) and trabecular BMD (Tb.BMD)) at 5 μm^3^ voxel resolution in a 1 mm^2^ region beginning 100 μm proximal to the distal growth plate. Parameters were determined using Scanco analysis software.

Destructive 3-point bend testing {#s4-4}
--------------------------------

Destructive 3-point bend tests were performed on femurs and compression tests on caudal vertebrae 6 and 7 using an Instron 5543 load frame and load cell (100N for mouse femurs and 500N for mouse caudal vertebrae and rat bones) (Instron Limited, High Wycombe, Buckinghamshire, UK) as described ([@bib8]). Bones were positioned horizontally on custom supports and load was applied perpendicular to the mid-diaphysis with a constant rate of displacement of 0.03 mm/s until fracture. Vertebrae were bonded in vertical alignment to a custom anvil support using cyanoacrylate glue and load was applied vertically at a constant rate of displacement of 0.03 mm/s and a sample rate of 20 Hz. Yield load, maximum load, fracture load, stiffness and toughness (Energy dissipated prior to fracture) were determined from femur load displacement curves and yield load, maximum load and stiffness from caudal vertebrae load displacement curves.

Osteoclast histomorphometry {#s4-5}
---------------------------

Osteoclast numbers were determined according to the American Society for Bone and Mineral Research system ([@bib16]) in paraffin sections from decalcified mouse femurs stained for tartrate resistant acid phosphatase (TRAP) activity, counterstained with aniline blue and imaged using a Leica DM LB2 microscope and DFC320 digital camera ([@bib10]). A montage of nine overlapping fields covering an area of 1 mm^2^ located 0.2 mm below the growth plate was constructed for each bone. BV/TV was measured, and osteoclast numbers and surface were determined in trabecular bone normalised to total bone surface ([@bib10]).

Alcian blue and Van Gieson staining of retained cartilage {#s4-6}
---------------------------------------------------------

Paraffin sections from decalcified mouse femurs were stained with Alcian blue van Gieson. Sections were imaged using a Leica DM LB2 microscope at a resolution of 920 pixels/mm. The trabecular region of interest (ROI) was defined as a 1 mm^2^ region beginning 100 μm proximal to the distal growth plate. The cortical ROI was defined as two 1.0 × 0.3 mm regions located 100 μm proximal to the distal growth plate each containing one femoral cortex. Blinded samples were analysed to determine bone area (B.Ar) and cartilage area (Cartilage.Ar) for each ROI using the Threshold and Colour Threshold functions of ImageJ. Cartilage area as a proportion of bone area (Cartilage.Ar/B.Ar) was then determined for both trabecular and cortical bone.

Cell culture, transfection and assessment of cell multinucleation {#s4-7}
-----------------------------------------------------------------

Human monocyte-derived macrophages were separated from healthy donor buffy coats by centrifugation through a Histopaque 1077 (Sigma) gradient and adhesion purification. Following Histopaque separation, peripheral blood mononuclear cells were re-suspended in RPMI (Life Technologies) and monocytes purified by adherence for 1 hr at 37°C, 5% CO~2~ in twelve-well plates. The monolayer was washed three times with HBSS to remove non-adherent cells and monocytes were differentiated for 3 days in RPMI medium containing 20 ng/ml M-CSF and 20 ng/ml recombinant human RANKL (PeproTech, UK). After 3 days of culture, mononucleated TRAP positive osteoclasts were obtained and transfected using Dharmafect 1 (Dharmacon) diluted in OPTIMEM medium (1:50 Invitrogen). siGENOME SMARTpools (100 nM, Dharmacon SMART pool) targeting human *APPL2*, *ATP8B2*, *BCAT1*, *DEPTOR*, *DOT1L*, *EGFR*, *EML1*, *EPS15*, *IGSF8*, *PIK3CB*, *RNF125*, *SLC1A4* and *SLC40A1* were used for RNAi and a non-targeting siRNA pool was used as the scrambled control siRNA. Primer sequence information is available in Supplementary Method 1. At the end of the culture (Day 5), osteoclasts were fixed in formalin, stained for TRAP and imaged. Transfection experiments were performed with four donors per si-RNA and three technical replicates in 12-well plates. Following the transfection, the number of nuclei in each TRAP-positive cell was counted to obtain the percentage of cells with 1, 2, three and \>4 nuclei, relative to numbers of nuclei in cells transfected with scrambled control siRNA.

Bone marrow-derived osteoclasts were isolated from 12 week old LEW and WKY rats by flushing bone marrow cells in DMEM (Thermo Fisher) supplemented with 25 mM HEPES buffer (Sigma), 25% fetal bovine serum (Labtech), penicillin/streptomycin (100 units/ml; Thermo Fisher). Bone marrow cells were differentiated into osteoclasts in DMEM containing 20 ng/ml M-CSF and 20 ng/ml recombinant rat RANKL (PeproTech, UK) for 6 days in Petri dishes (Nunc). At the end of the culture, cells were fixed in formalin and stained with Giemsa to visualise nuclei and count osteoclasts.

Quantitative RT-PCR {#s4-8}
-------------------

For quantitative RT-PCR (RT-qPCR), total RNA was extracted from human and rat osteoclasts using the TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesised using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). A total of 10 ng cDNA for each sample was used and all RT-qPCR reactions were performed on a ViaA 7 Real-Time PCR System (Life Technologies, Carlsbad, CA) using Brilliant II SYBR Green QPCR Master Mix (Agilent, Santa Clara, CA). Results were analysed by the comparative Ct method using ViiA 7 RUO software, and each sample was normalised relative to *HPRT* expression.

In vitro resorption {#s4-9}
-------------------

In vitro resorption activity of human osteoclasts was measured on Osteo Assay Surface 96 well plates (hydroxyapatatite surfaces) (Corning). siRNA transfected cells were incubated with cell dissociation buffer (Sigma) and 10^5^ cells/well were seeded in Osteo Assay Surface Plates. After 2 days of culture with 20 ng/ml M-CSF and 20 ng/ml recombinant human RANKL (PeproTech, UK), the wells were rinsed twice with PBS and incubated with 10% bleach solution for 30 min at room temperature. The wells were then washed twice with PBS and allowed to dry at room temperature. Individual resorption pits were imaged by light microscopy. Images were inverted and processed using Photoshop to yield high-contrast images and show the resorbed areas in black against a white background. Binary images of each individual well were then subjected to automated analysis (ImageJ), using constant 'threshold' and 'minimum particle' levels, to determine the number and surface area of resorbed pits.

Statistical analysis {#s4-10}
--------------------

Data are presented as mean ± standard deviations (SD) and analysed using GraphPad Prism software (version 7.02; GraphPad). Normally distributed data were analysed by two tailed Student's t test. Relationships between micro-CT parameters and in vitro osteoclastogenesis were determined by Pearson correlation. Frequency distributions of bone mineral densities obtained by x-ray microradiography were compared using the Kolmogorov-Smirnov test. Differences in percentage of control following si-RNA knockdown in primary osteoclasts were tested for significance using a one-sample-t test.

IMPC mutant lines were compared to C57BL6/N strain-specific reference ranges established for all parameters using 16 week-old female wild-type mice (n = 320) obtained from control cohorts. Strains in which a structural or functional parameter was ±2.0 SD from the C57BL6/N reference mean were considered as outliers.

The hypergeometric test was used to determine whether the MMnet network (n = 190 rat genes, of which 178 genes had a unique human orthologue) was enriched for genes with a GWAS signal (p\<10^−6^) for traits related to bone and height ([Table 1](#table1){ref-type="table"}) in the NHGRI-EBI Catalog of published GWAS (<https://www.ebi.ac.uk/gwas/>). Over-representation of GWAS gene signals in MMnet was assessed in comparison with the whole set of eQTLs (n = 1527 genes, of which 1448 genes had a unique human orthologue) that were previously mapped in multinucleating macrophages ([@bib29]). Biomart was used to map rat genes to the human orthologues (one-to-one orthology) using Ensembl rel. 98.
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**Decision letter after peer review:**

Thank you for submitting your article \"A trans-eQTL network regulates osteoclast multinucleation and bone mass\" for consideration by *eLife*. Your article has been reviewed by Clifford Rosen as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Natalie Sims (Reviewer \#1); Nathan J Pavlos (Reviewer \#2); Steven Munger (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript describes a systems genetics analysis using a previously identified transcriptomic network (MMNet) found to be important in the context of macrophage nucleation. Specifically, the authors integrate the MMNet with human eBMD GWAS data and results from a large-scale mouse phenotyping effort to identify novel genes impacting osteoclast function and bone mass. All reviewers thought the manuscript was well-written and an outstanding example of the power of systems genetics. The phenotypic assessment of novel genes using large-scale mutant mouse phenotyping scans was also viewed as a significant strength. However, the reviewers questioned whether this work provided direct evidence that the MMnet genes are bona fide regulators of osteoclast fusion/multinucleation and that few mechanistic details were provided. To improve the manuscript we recommend providing a more detailed analysis of the bone phenotypes (i.e. better analysis of osteoclasts (e.g. simply counting nuclei) and, to the extent possible, osteoblast contributions to the phenotype). It was suggested that a more detailed and balanced assessment of at least one of the mutant mice be provided, e.g. Slc40a1 is a good candidate given it was deleted in a macrophage-specific background. Below are the detailed comments from the reviewers.

Essential revisions:

1\) The term \"osteoclast multinucleation\" is used throughout the manuscript, but it is not very accurate. In each of the gene suppression or gene deletion studies, they observed reduced formation of osteoclasts, but it is not clear at which stage the genes function -- they may be involved in osteoclast precursor maturation (TRAP+ mononuclear cells have not been counted), or may be involved in initiation of binucleation. At no point have number of nuclei been counted. All that can be said at this point is that they are involved in osteoclast formation.

2\) The authors state multiple times (particularly in the Introduction and Discussion section) that multinucleation capability correlates with resorptive activity, but this is not true. There are many conditions (e.g. Src deletion, Pyk2 deletion, ClC-7 deficiency -- the so-called \"osteoclast-rich osteopetroses\") where multinucleation occurs but osteoclasts are non-functional (or have impaired function).

3\) In the phenotypic analysis of the mice, the authors explain all phenotypes by a change in osteoclast generation with no analysis presented on the other side of the equation -- osteoblast numbers and bone formation rate. This oversight is disappointing. It is not clear that the high bone mass phenotypes are truly osteopetrotic -- no data on cartilage remnants is shown.

4\) It is very concerning that the number of mice analysed by histomorphometry is a very small subset of those analysed by micro-CT (e.g. for Bcat1 it is n=4 rather than n=8, and for Slc40a1 it is 4-5 instead of n=8). These are very low sample numbers indeed, and for the Slc40a1 data it is not clear that any affect on osteoclast formation is observed due to the biological variance. How were the subset of samples chosen for histomorphometry? Why were 50% of the samples excluded?

5\) The description of osteoclastogenesis assays is very limited. Although osteoclast formation is suppressed by the siRNA experiments, there is no information presented about whether it is truly an effect on \"multinucleation\" or an effect on precursor differentiation. Was there any suppression in the number of TRAP+ mononuclear cells? Were binucleated cells observed? Did the osteoclasts formed contain less nuclei than the control osteoclasts.

6\) siRNA is used to assess the affect of gene suppression on osteoclast formation, but no evidence is presented to show success of the knockdown.

7\) Images shown in Figure 1E and Figure 3B for si-scrambled and si-DCSTAMP are identical. Were all these analyses performed together? If so, the data should not be presented twice.

8\) Although deletion of Bcat1, Pik3cb, Atp8b2, Slc40a1, and Appl2 all lead to reduced osteoclast formation and increased BV/TV, the phenotypes are different in their effects on strength and cortical bone. This is not discussed.

9\) The authors analyse knockout mice of 12 candidate co-regulatory genes with modest to mild bone phenotypes, some of which have been previously described in detail and implicated in osteoclast function and bone mass including Pik3cb, Deptor and Slc40a1. With the exception of Slc40a1, all of the bone parameters assessed arise from global or heterozygous (Atp8b2) knockout mice from a single age-point/sex (i.e. 12-wk old male Bcat1 and others 16-week old female) making it difficult to assess the penetrance and robustness of bone phenotype across both sexes and whether the phenotype resolves or increases with age as is frequently observed in the bones of mice harbouring dysfunctional osteoclasts. Moreover, changes in femur length observed (e.g. for Igsf8 and WKY rats) imply that bone phenotype(s) are not restricted to osteoclasts but likely extends to other bone/cartilage resident cell types such as chondrocytes or osteoblasts and/or osteocytes. However, the authors make no provisions to address cell-autonomous defects experimentally nor has this been acknowledged in the Discussion section, which misleads the reader. Can the authors lend any information as to whether the phenotypes are maintained across both sexes and time? Further, are the MMnet genes expressed and/or functionally implicated in other bone/cartilage resident cells? As a minimum this needs to be addressed in the Discussion section and statements implicating osteoclasts tempered accordingly.

10\) Similarly, the notion that the low bone mass phenotype and shorter bones in WKY rats reflects disturbances in osteoclast multinucleation is unsubstantiated by the data presented in Figure 2---figure supplement 1. There has been little attempt to address this at either at the histological/histomorphometric level or ex vivo generation of osteoclasts which is well within their remit. Do the authors have any evidence that osteoclast numbers and/or fusion rates are increased in WKY? I can only identify data pertaining to multinucleated giant cells in the study of Kang et al., 2014. This data is important as it underscores the premise of the MMnet network from which ensuing target fusion genes and functional studies on osteoclasts are derived. As an aside, caution should be exercised when drawing direct comparisons between multinucleation regulatory networks of macrophage-derived giant cells and osteoclasts given that they are enzymatically and functionally distinct polykaryons.

11\) In their present form, the in vitro studies remain too premature to draw meaningful correlations with in vivo data and thus fail to support conclusions that these genes regulate osteoclast fusion and/or resorption. Given the ready access to the IMPC mice it is surprising that the authors did not capitalize on this resource to validate cell-autonomous defects on osteoclast formation and multinucleation parameters ex vivo for at least a subset of the identified MMnet genes. Such data would go a long way towards substantiating claims and strengthening the resolve of the human osteoclast data, which are derived from siRNA-mediated transient knockdown experiments for which the efficiency and specificity of targeting remains incomplete for many of the described MMnet genes. This is of particular importance for the Slc40a1(Ferroportin) gene given the claims that \" \"Slc40a1 acts as an important determinant of adult bone mass and.... by directly regulating osteoclast multinucleation and function.\", and in light of the discrepancies observed between the bone phenotypes in this study with those detailed by Wang et al., 2019, who reported reduced bone mass upon Slc40a1 deletion and accelerated osteoclast differentiation/fusion in the same LysoM-Cre conditional knockout model.

12\) Although collectively the data presented in this study encompass a nice synergy between genetic and high through bone phenotyping, individually the data offers few mechanistic insights into the roles of the identified multinucealation factors in osteoclasts. Given the robust inhibition of osteoclast multinucleation following Slc40a1, any additional data here would be welcomed to strengthen is potential role a regulator of osteoclast fusion.
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Author response

> Summary:
>
> This manuscript describes a systems genetics analysis using a previously identified transcriptomic network (MMNet) found to be important in the context of macrophage nucleation. Specifically, the authors integrate the MMNet with human eBMD GWAS data and results from a large-scale mouse phenotyping effort to identify novel genes impacting osteoclast function and bone mass. All reviewers thought the manuscript was well-written and an outstanding example of the power of systems genetics. The phenotypic assessment of novel genes using large-scale mutant mouse phenotyping scans was also viewed as a significant strength. However, the reviewers questioned whether this work provided direct evidence that the MMnet genes are bona fide regulators of osteoclast fusion/multinucleation and that few mechanistic details were provided. To improve the manuscript we recommend providing a more detailed analysis of the bone phenotypes (i.e. better analysis of osteoclasts (e.g. simply counting nuclei) and, to the extent possible, osteoblast contributions to the phenotype). It was suggested that a more detailed and balanced assessment of at least one of the mutant mice be provided, e.g. Slc40a1 is a good candidate given it was deleted in a macrophage-specific background. Below are the detailed comments from the reviewers.
>
> Essential revisions:
>
> 1\) The term \"osteoclast multinucleation\" is used throughout the manuscript, but it is not very accurate. In each of the gene suppression or gene deletion studies, they observed reduced formation of osteoclasts, but it is not clear at which stage the genes function -- they may be involved in osteoclast precursor maturation (TRAP+ mononuclear cells have not been counted), or may be involved in initiation of binucleation. At no point have number of nuclei been counted. All that can be said at this point is that they are involved in osteoclast formation.

We thank the reviewer for highlighting this important point and agree it is not clear in the text that the number of nuclei in each differentiated mature osteoclast was determined (see also our response to comment 5). We also agree with the reviewer that osteoclast differentiation and fusion/multinucleation are two distinct cellular stages and any gene silencing experiment should take this into account. We now clarify that all RNAi experiments were performed at Day 3, in RANKL-differentiated and TRAP positive mononucleated osteoclasts, to assess the effect of gene silencing on cell multinucleation/fusion *per se* at day 6. This experimental design allows working on fully differentiated TRAP+ osteoclasts and focus on cell fusion/multinucleation during a 48-hour period.

We have updated the Materials and methods section, text and figure legends to clarify the experimental design. Furthermore, in accordance with comment 5, we now include the percentage of TRAP+ mononuclear, binuclear and trinuclear osteoclasts following si-RNA for each gene (Figure 4---figure supplement 2 Panel E and response to comment 5).

> 2\) The authors state multiple times (particularly in the Introduction and Discussion section) that multinucleation capability correlates with resorptive activity, but this is not true. There are many conditions (e.g. Src deletion, Pyk2 deletion, ClC-7 deficiency -- the so-called \"osteoclast-rich osteopetroses\") where multinucleation occurs but osteoclasts are non-functional (or have impaired function).

We thank the reviewer for highlighting this omission and we have amended the introduction accordingly and added an additional reference to ensure accuracy and clarity throughout. (Introduction).

> 3\) In the phenotypic analysis of the mice, the authors explain all phenotypes by a change in osteoclast generation with no analysis presented on the other side of the equation -- osteoblast numbers and bone formation rate. This oversight is disappointing. It is not clear that the high bone mass phenotypes are truly osteopetrotic -- no data on cartilage remnants is shown.

We are very grateful to the reviewer for raising this important point. As suggested by the reviewer we quantified the fraction of retained cartilage in both trabecular and cortical bone in distal femur sections from (i) *Bcat1^-/-^* and WT control mice and (ii) *Slc40a1*^∆lysMCre^ and *Slc40a1*^flox/flox^ controls by staining with Alcian Blue Van Geison. Consistent with impaired osteoclast function in these mutant mice we observed increased retained cartilage in both trabecular and cortical bone in *Bcat1^-/-^* mice and increased retained cartilage in trabecular bone in *Slc40a1^-/-^* mice. We have added these data to Figure 2---figure supplement 1 and Figure 5---figure supplement 2 and have updated the Materials and methods section, Results section and figure legends accordingly.

> 4\) It is very concerning that the number of mice analysed by histomorphometry is a very small subset of those analysed by micro-CT (e.g. for Bcat1 it is n=4 rather than n=8, and for Slc40a1 it is 4-5 instead of n=8). These are very low sample numbers indeed, and for the Slc40a1 data it is not clear that any affect on osteoclast formation is observed due to the biological variance. How were the subset of samples chosen for histomorphometry? Why were 50% of the samples excluded?

As requested by the reviewers, we have now included histomorphometry data from the full set of n=8 samples for *Bcat1^-/-^* and *Slc40a1^-/-^* mice (see revised Figure 2 and Figure 5).

> 5\) The description of osteoclastogenesis assays is very limited. Although osteoclast formation is suppressed by the siRNA experiments, there is no information presented about whether it is truly an effect on \"multinucleation\" or an effect on precursor differentiation. Was there any suppression in the number of TRAP+ mononuclear cells? Were binucleated cells observed? Did the osteoclasts formed contain less nuclei than the control osteoclasts.

We thank the reviews for highlighting this important issue. As discussed in point 1 we now clarify that the number of nuclei in each differentiated mature osteoclast were determined following RNAi. This comprehensive analysis enables determination of the consequences of si-RNA knockdown on osteoclast multinucleation/fusion in addition to cell differentiation and maturation. Accordingly, we have revised Figure 4---figure supplement 1 to include the percentage of TRAP+ mono, bi and trinucleated osteoclasts following si-RNA. We have updated the methods, the text and the figure legends to clarify the experimental design.

> 6\) siRNA is used to assess the affect of gene suppression on osteoclast formation, but no evidence is presented to show success of the knockdown.

Quantification of gene knockdown following si-RNA was previously included in Figure 4---figure supplement 1 and referred to in subsection "Human MMnet orthologues regulate osteoclast multinucleation and resorption". We have now emphasised these data clearly in the text.

> 7\) Images shown in Figure 1E and Figure 3B for si-scrambled and si-DCSTAMP are identical. Were all these analyses performed together? If so, the data should not be presented twice.

We thank the reviews for highlighting this error we have now amended Figure 2 accordingly.

> 8\) Although deletion of Bcat1, Pik3cb, Atp8b2, Slc40a1, and Appl2 all lead to reduced osteoclast formation and increased BV/TV, the phenotypes are different in their effects on strength and cortical bone. This is not discussed.

We thank the reviewers for highlighting this important point. We now consider this point in detail and have amended the Discussion section.

> 9\) The authors analyse knockout mice of 12 candidate co-regulatory genes with modest to mild bone phenotypes, some of which have been previously described in detail and implicated in osteoclast function and bone mass including Pik3cb, Deptor and Slc40a1. With the exception of Slc40a1, all of the bone parameters assessed arise from global or heterozygous (Atp8b2) knockout mice from a single age-point/sex (i.e. 12-wk old male Bcat1 and others 16-week old female) making it difficult to assess the penetrance and robustness of bone phenotype across both sexes and whether the phenotype resolves or increases with age as is frequently observed in the bones of mice harbouring dysfunctional osteoclasts. Moreover, changes in femur length observed (e.g. for Igsf8 and WKY rats) imply that bone phenotype(s) are not restricted to osteoclasts but likely extends to other bone/cartilage resident cell types such as chondrocytes or osteoblasts and/or osteocytes. However, the authors make no provisions to address cell-autonomous defects experimentally nor has this been acknowledged in the Discussion section, which misleads the reader. Can the authors lend any information as to whether the phenotypes are maintained across both sexes and time? Further, are the MMnet genes expressed and/or functionally implicated in other bone/cartilage resident cells? As a minimum this needs to be addressed in the Discussion section and statements implicating osteoclasts tempered accordingly.

Skeletal samples from mice, harbouring global deletion of the 12 candidate co-regulatory genes, were examined as part of The Origins of Bone and Cartilage Disease (OBCD) Programme and International Mouse Phenotyping Consortium (IMPC). Details of these programmes are referenced in subsection "Animals". In the IMPC programme all mice are sacrificed at 16 weeks of age and skeletal phenotypes determined in female samples (n=2-6 per line) and joint phenotypes determined in male samples (n=2-6 per line) by the OBCD programme. Thus, detailed skeletal phenotype data is only available from 16 week old female mice and not from males or older animals. Nevertheless, the broad IMPC screen also identified increased bone mineral content by DEXA in male Atp8b2^+/-^ mice at 16 weeks of age. We agree with the referees that since these mice are global knockouts the observed skeletal phenotypes may also reflect the consequences of gene deletion in non-monocyte/macrophage lineages. The Discussion section has been amended accordingly.

> 10\) Similarly, the notion that the low bone mass phenotype and shorter bones in WKY rats reflects disturbances in osteoclast multinucleation is unsubstantiated by the data presented in Figure 2---figure supplement 1. There has been little attempt to address this at either at the histological/histomorphometric level or ex vivo generation of osteoclasts which is well within their remit. Do the authors have any evidence that osteoclast numbers and/or fusion rates are increased in WKY? I can only identify data pertaining to multinucleated giant cells in the study of Kang et al., 2014. This data is important as it underscores the premise of the MMnet network from which ensuing target fusion genes and functional studies on osteoclasts are derived. As an aside, caution should be exercised when drawing direct comparisons between multinucleation regulatory networks of macrophage-derived giant cells and osteoclasts given that they are enzymatically and functionally distinct polykaryons.

The reviewers have raised an important point; to address it we have performed osteoclast cultures from WKY and LEW rats (n=3/group). We cultured rat osteoclasts for 6 days in the presence of M-CSF and RANKL and found relatively larger osteoclasts with a greater number of nuclei in WKY rats. This increased multinucleation/fusion was also associated with increased expression levels of two key genes implicated in osteoclast fusion: Trem2, the master-regulator of MMnet and Nfatc1, the master-regulator of transcriptional reprogramming of osteoclast fusion. These data are now included in the revised version of Figure 1 and the text/figure legends changed accordingly.

> 11\) In their present form, the in vitro studies remain too premature to draw meaningful correlations with in vivo data and thus fail to support conclusions that these genes regulate osteoclast fusion and/or resorption. Given the ready access to the IMPC mice it is surprising that the authors did not capitalize on this resource to validate cell-autonomous defects on osteoclast formation and multinucleation parameters ex vivo for at least a subset of the identified MMnet genes. Such data would go a long way towards substantiating claims and strengthening the resolve of the human osteoclast data, which are derived from siRNA-mediated transient knockdown experiments for which the efficiency and specificity of targeting remains incomplete for many of the described MMnet genes. This is of particular importance for the Slc40a1(Ferroportin) gene given the claims that \" \"Slc40a1 acts as an important determinant of adult bone mass and.... by directly regulating osteoclast multinucleation and function.\", and in light of the discrepancies observed between the bone phenotypes in this study with those detailed by Wang et al., 2019, who reported reduced bone mass upon Slc40a1 deletion and accelerated osteoclast differentiation/fusion in the same LysoM-Cre conditional knockout model.

The reviewers raise an important question. Rapid-throughput skeletal phenotyping of IMPC mutant mice was performed as part of the Wellcome Trust funded Origins of Bone and Cartilage Disease Programme (Bassett et al., 2012; Kemp et al., 2017; Medina-Gomez et al., 2017; Morris et al., 2018; and reviewed in Freudenthal et al., 2018). In this programme, mice were generated at the Sanger Institute and only skeletal samples provided for phenotype analysis. Importantly, once samples are collected at 16 weeks of age colonies of IMPC mice are not maintained and are only archived as embryo's or sperm. Thus, we are unable to perform primary osteoclast cultures from the 12 IMPC knockout lines.

Furthermore, in Figure 4---figure supplement 1 (Panel B) we now show that the efficiency of si-RNA knockdown was greater than 80% for all genes studied in human osteoclasts.

Importantly, the RNAi studies in human osteoclasts demonstrated that changes in multinucleation correlated with resorption in vitro and trabecular bone volume in vivo (Figure 4E and F).

With regard to studies in *Slc40a1* mutant mice, *Slc40a1* encodes the mammalian iron transporter (ferroportin) and its deficiency in the myeloid lineage is predicted to have two main consequences; (i) intracellular ferrous (Fe^2+^) iron levels will increase because of a defect in export. This is likely to impair osteoclast activity, fusion and multinucleation as these are energy-demanding processes that require appropriate levels of intracellular iron, and (ii) defective iron export in myeloid cells is predicted to reduce iron concentrations in the extracellular bone microenvironment and may result in defective osteoclast-osteoblast coupling.

We are grateful that the editor agreed that additional studies of these cell-intrinsic and osteoclast-osteoblast coupling pathways were beyond the scope of the current manuscript, which is focused on the validation of a *trans*-eQTL network regulating osteoclast multinucleation and bone mass.

> 12\) Although collectively the data presented in this study encompass a nice synergy between genetic and high through bone phenotyping, individually the data offers few mechanistic insights into the roles of the identified multinucealation factors in osteoclasts. Given the robust inhibition of osteoclast multinucleation following Slc40a1, any additional data here would be welcomed to strengthen is potential role a regulator of osteoclast fusion.

We agree with the reviewers that additional mechanistic data relating iron metabolism to the regulation of osteoclast multinucleation would enhance these studies but we are grateful to the editor for agreeing that such additional experiments are beyond the scope of the current manuscript.
